György M. Keserü & David Swinney 
Thermodynamics and Kinetics of Drug Binding [PDF ebook] 

SECTION I: THERMODYNAMICS
The Binding Thermodynamics of Drug Candidates
Van’t Hoff-based Thermodynamics
Computation of Drug Binding Thermodynamics
Thermodynamics Guided Optimizations in Medicinal Chemistry
From Molecular Understanding to Structure-Thermodynamic Relationships: the Case of Acetylcholine Binding Proteins
Thermodynamics in Lead Optimisation
Lead Optimization Case Study: Thermodynamic Profiling of Carbonic Anhydrase Inhibitors
SECTION II: KINETICS
Drug-Target Residence Time
Experimental Methods to Determine Binding Kinetics
Challenges in the Medicinal Chemical Optimisation of Binding Kinetics
Computational Approaches for Studying Drug Binding Kinetics
The Use of Structural Information to Understand Binding Kinetics
Importance of Drug-Target Residence Time at G Protein-coupled Receptors — a Case for the Adenosine Receptors
Case Study: Angiotensin Receptor Blockers (ARBs)
The Kinetics and Thermodynamics of Staphylococcus aureus Fab I Inhibition
SECTION III: PERSPECTIVE
Thermodynamics and Binding Kinetics in Drug Discovery

György Keserü obtained his Ph.D. at the University of Budapest (Hungary) and joined Sanofi-Aventis heading a chemistry research lab. In 1999, he moved to Gedeon Richter as the Head of Computer-aided Drug Discovery, being appointed as the Head of Discovery Chemistry in 2007. Since 2003, he also holds a research professorship at the Budapest University of Technology and Economics. His research interests include medicinal chemistry, drug design, and in silico ADME. He has published over 150 papers and more than 10 books and book chapters. Recently he was granted the Prous award by the European Federation of Medicinal Chemistry, EFMC.
David Swinney obtained his Ph D at the University of Washington in Seattle (USA). He spent 8 years at Syntex Palo Alto before moving on to Roche where he was serving as Department Head of Inflammation and Respiratory Diseases and later as Director of Biochemical Pharmacology. In 2010 he founded the Institute for Rare and Neglected Diseases, which is a non-profit drug discovery organization. Dr. Swinney is an international expert in enzymology and pharmacology with special interest in molecular mechanism of drug action and binding kinetics.